ClinicalTrials.gg

Acute Coronary Syndrome clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 1,491 studies for Acute Coronary Syndrome across more than 10 countries. 272 are recruiting or about to start. 1,024 of them are mainly about Acute Coronary Syndrome (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17.

ClinicalTrials.gov finds 1,988 studies for Acute Coronary Syndrome. How that becomes 1,491 hereChecked on ClinicalTrials.gov . The studies here are updated every night.

This page counts the studies the registry files under Acute Coronary Syndrome, and those it files under no condition that list Acute Coronary Syndromethemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. Only this comparison waits for its turn: it is asked again about once a week, so between two checks the registry's number can run a little ahead of it. How condition pages count

  1. 1,988Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −21List Acute Coronary Syndrome as a condition, but the registry did not file them under itMost often written as “Non ST Segment Elevation Acute Coronary Syndrome” (6), “Non-ST-elevation Acute Coronary Syndrome” (3), and “Acute Coronary Syndrome Without ST Elevation on Electrocardiogram” (2). The registry filed them under other conditions only, most often Angina, Unstable (5) and Non-ST Elevated Myocardial Infarction (4).
  3. −476Match it another way172 name it in the title, 2 in a keyword, and 302 by a synonym or other text the search reads.
  4. 1,491The count on this page25 of them list Acute Coronary Syndrome in their own words; the registry filed them under no condition.

Status

Completed
781
Status unknown
267
Recruiting
195
Terminated
85
Not yet recruiting
71
Active, not recruiting
53

Phase

Phase 4
236
Phase 3
128
Phase 2
88
Phase 1
41
Early Phase 1
6

Where

United States
265
China
185
Italy
138
France
127
Canada
104
United Kingdom
93

Who develops what

Add Acute Coronary Syndrome to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 7 programs from 6 companies, 5 with this as their studies’ main aim; 2 with a live phase 3 study; 3 primary completions in the next 12 months. Compare Novartis, AO GENERIUM and Jiangsu vcare pharmaceutical technology here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
ClopidogrelRecent, limited
Evidence
  • NCT06577519 · Jiangsu vcare pharmaceutical technology co., LTD · Phase 3 · live · comparator · “Clopidogrel” · registered Aug 2024
  • NCT02052635 · AstraZeneca · Phase 4 · comparator · “clopidogrel” · registered Jan 2014
  • NCT01864005 · AstraZeneca · Phase 4 · comparator · “Clopidogrel” · registered May 2013
  • NCT01603082 · AstraZeneca · Phase 4 · comparator · “Clopidogrel” · registered May 2012
  • NCT01294462 · AstraZeneca · Phase 3 · comparator · “Clopidogrel” · registered Feb 2011
Sanofi35% of its industry studiesUS: off-patent, 13 generics marketedEU: off-patent, 11 generics authorized11 study
Tissue Plasminogen ActivatorRecent, limited
Evidence
  • NCT07146360 · AO GENERIUM · Phase 3 · comparator · “Actilyse® (Boehringer Ingelheim Pharma GmbH and Co.KG, Germany)” · registered Aug 2025
Boehringer Ingelheim28% of its industry studiesUS: Hoffmann-La Roche (FDA 1987)11 study
HeparinEarlier only
Evidence
  • NCT01087723 · Novartis · Phase 3 · comparator · “Heparin” · registered Mar 2010
  • NCT01076764 · Sanofi · Phase 3 · comparator · “UFH” · registered Feb 2010
  • NCT00932100 · Regado Biosciences, Inc. · Phase 2 · comparator · “Heparin” · registered Jul 2009
Azidus Brasil18% of its industry studiesUS: off-patent, 20 generics marketed00 studies

3 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
sumecigrel☆ Track1 live phase-3 study: NCT06577519Jiangsu vcare pharmaceutical technology co., LTD
inclisiranApproved: US 2021 · EU 2020☆ Track1 live phase-3 study: NCT07102628Novartis

The 2 in phase 3 with the nearest primary completion, of 7 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (3)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 30 Dec 2026 est.sumecigrel · Jiangsu vcare pharmaceutical technology co., LTD · Phase 3 main aimvs ClopidogrelNCT06577519 Efficacy and Safety Study of Vicagrel in Patients With Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI) — primary endpoint: The incidence of MACE · 1,000 enrolled
  • 16 Jan 2027 est.inclisiran · Novartis · Phase 3 main aimNCT07102628 Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes — primary endpoint: Percent change in LDL-C · 305 enrolled
  • 8 Feb 2027 est.orticumab · Abcentra · Phase 2 main aimNCT06927739 Focused Orticumab Research for Treating Inflammation in Coronary Arteries — primary endpoint: Percent change from baseline of the mean Fat Attenuation Index (FAI) score for the 3 coronary arteries (RCA, LAD and LCX) for orticumab compared to placebo at 24 weeks · 240 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Acute Coronary Syndrome studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here P2Y12 inhibitors 9 open · NSAIDs 7 open · Statins 4 open · Factor Xa inhibitors 2 open · PCSK9 inhibitors 2 open

Coming up

80studies finish main data collection within a year5 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 195 Acute Coronary Syndrome studies recruiting now, 144 (74%) set no upper age limit and 19 (10%) stop at 75 or younger. 15 (8%) take children under 18. 1 (1%) are for women only and 0 (0%) for men only; 15 (8%) take healthy volunteers.

Recruiting studies that take each age, of 195
AgeWomenMen
1013 (7%)13 (7%)
18165 (85%)164 (84%)
30187 (96%)186 (95%)
40189 (97%)188 (96%)
50188 (96%)187 (96%)
65190 (97%)189 (97%)
75185 (95%)184 (94%)
85159 (82%)158 (81%)

Across all 1,491 studies, recruiting or not: 12% stop at 75 or younger and 4% at 65; 7% take children; <1% are for women only and 1% for men only; 7% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Acute Coronary Syndrome studies take

Of 92 phase 4 interventional studies under Acute Coronary Syndrome, half reached primary completion within 42 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 13 mo2–14 · 16 studies——
Phase 228 mo17–39 · 30 studies——
Phase 341 mo24–52 · 39 studies——
Phase 442 mo26–60 · 92 studies—45 mo27–67 · 85 studies
Interventional, no phase34 mo17–46 · 228 studies—34 mo16–46 · 213 studies
Observational35 mo18–68 · 277 studies29 mo20–42 · 34 studies36 mo18–71 · 243 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 19, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 1,491. Browse all 1,491 → or search them.